Baseline Cytogenetic Testing Performed on Bone Marrow

This measure is to be reported for all patients aged 18 years and older with myelodysplastic syndrome (MDS) or acute leukemia — a minimum of **once** per reporting period.

Measure description

Percentage of patients aged 18 years and older with a diagnosis of MDS or an acute leukemia who had baseline cytogenetic testing performed on bone marrow

What will you need to report for each patient with MDS or acute leukemia for this measure?

If you select this measure for reporting, you will report:

 Whether or not you performed a baseline cytogenetic test¹ on bone marrow (regardless of when the baseline testing was performed)

What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to perform a baseline cytogenetic test on bone marrow, due to:

- Medical reasons (eg, no liquid bone marrow or fibrotic marrow) OR
- Patient reasons (eg, at time of diagnosis receiving palliative care or not receiving treatment as defined above) OR
- System reasons (eg, patient previously treated by another physician at the time cytogenetic testing performed)

In these cases, you will need to indicate which reason applies, and specify the reason on the worksheet and in the medical chart. The office/billing staff will then report a code with a modifier that represents these valid reasons (also called exclusions).

¹Baseline cytogenetic testing refers to testing that is performed at time of diagnosis or prior to initiating treatment (transfusion, growth factors, or antineoplastic therapy) for that diagnosis.

PQRI 2009 Measure 67. Effective Date 01/01/2009

^{© 2006–7} American Medical Association and American Society of Hematology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. (Disclaimers, Copyright and other Notices indicated on the Coding Specifications document are incorporated by reference)